DaVita (DVA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$14.0B

Revenue (quarter)

$3.6B

Revenue growth (year over year)

+5.17%

Gross profit (trailing twelve months)

$4.5B

Gross margin

32.36%

Net income (trailing twelve months)

$1.2B

Net income (quarter)

$343.2M

Net income growth (year over year)

+24.71%

Net margin

8.49%

Return on equity

397.24%

EPS (trailing twelve months)

$12.40

Book value per share

$12.45

P/E (trailing twelve months)

14.24

Price to book

11.18

Debt to assets

93.90%

Payout ratio

—

Dividend yield

—

Company profile

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

• Is DaVita (DVA) profitable?

  Yes. DaVita earned $1.2B in net income over the trailing twelve months, a net margin of 8.49%.

• How much revenue does DaVita (DVA) make?

  DaVita generated $14.0B in revenue over the trailing twelve months, up 5.17% year over year.

• What is DVA's P/E ratio?

  DaVita trades at 14.2 times trailing twelve-month earnings, on an EPS of $12.40.

• How do I buy stock in DaVita (DVA)?

  DVA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.